pipeline
A Platform Based r&d Strategy
Scinai’s R&D strategy is built on a VHH-based antibody platform applied across local and systemic formats. This platform support disciplined risk management and multiple paths to value creation.
VHH-Based Antibody Platform: Flexible Formats, Disciplined Validation
Scinai’s VHH-based antibody platform enables the design of compact, high-affinity binding domains that can be deployed across multiple therapeutic formats, including local delivery and systemic antibody constructs.
The platform supports selective development of mono-,
bi-, and tri-specific antibodies across immune-mediated and inflammatory diseases, with a focus on capital-efficient validation through lead programs.
The VHH programs are based on licensed technology from the Max Planck Institute for Multidisciplinary Sciences and University Medical Center Göttingen (Germany).
Multiple Blockbuster Opportunities
With positive proof-of-concept data across its lead programs, proven regulatory pathways, and strong external validation for our NanoAb drug candidates, Scinai’s platform approach creates multiple blockbuster-scale opportunities while preserving strategic and financing optionality.
PIPELINE
Focused & Derisked Strategy
Portfolio Role
Primary Platform Validator
Selective Innovation Track
Future Platform Expansion
Asset
Systemic bi-specific NanoAb
Target
IL-17A/F + Undisclosed
IL-17A/F
IL-4 / IL-4Rα, IL-13, TSLP
Target Indications
Moderate-Severe Psoriasis, PsA, HS
Mild–Moderate Psoriasis
TH2 Diseases: AD, Asthma, COPD
Development Status
Lead clones generated
First pre-clinical PoC completed
Lead clones generated
Next major milestone
In-vivo PoC
Second pre-clinical PoC with Sustained release formulation
In vivo PoC
FIH clinical trial
YE2027
Local
intradermal NanoAb
Systemic
multi-specific - NanoAb
TBD
TBD
Contact us
Get in touch to explore partnership opportunities and consult our CDMO specialists